Wall Street analyst estimates for Lipocine Inc. (LPCN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement.
Valuation Ratios
| Price / Book | 0.79 |
| EV / EBITDA | -1.23 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $428031 | $164990 | 0 | $16.1M | $500000 | -$2.9M | $11.2M | $2.0M |
| Cost of Revenue | 0 | 0 | 0 | $7.5M | 0 | $7.7M | $8.6M | $10.2M | 0 | $8.6M |
| Gross Profit | 0 | 0 | $428031 | -$7.3M | 0 | $8.5M | -$8.1M | -$13.0M | $11.2M | -$6.6M |
| Research & Development | $8.1M | $11.0M | $6.5M | $7.5M | $9.7M | 0 | 0 | 0 | $7.4M | 0 |
| Selling, General & Admin | $10.4M | $10.2M | $5.3M | $5.6M | $8.2M | $5.3M | $4.1M | $4.9M | $5.0M | $3.8M |
| Operating Expenses | $19.0M | $21.0M | $12.1M | $5.6M | $18.0M | $5.3M | $4.1M | $4.9M | $12.4M | $3.8M |
| Operating Income | -$18.5M | -$21.2M | -$11.3M | -$12.9M | -$18.0M | $3.1M | -$12.1M | -$17.9M | -$1.2M | -$10.4M |
| EBITDA | -$18.9M | -$21.2M | -$11.3M | -$12.2M | -$18.0M | -$430527 | -$10.7M | -$16.3M | $50139 | -$9.6M |
| Interest Expense | 0 | 0 | 0 | $343254 | $386618 | $203292 | $27098 | 0 | 0 | 0 |
| Pre-tax Income | -$19.0M | -$21.0M | -$11.7M | -$13.0M | -$21.0M | -$634199 | -$10.8M | -$16.4M | $9033 | -$9.6M |
| Income Tax | $752 | $700 | $700 | $200 | $200 | $200 | $681 | $755 | $681 | $200 |
| Net Income | -$19.0M | -$21.0M | -$11.7M | -$13.0M | -$21.0M | -$634399 | -$10.8M | -$16.4M | $8352 | -$9.6M |
| EPS | $-17.66 | $-17.79 | $-9.35 | $-8.54 | $-6.46 | $-0.19 | $-2.15 | $-3.14 | $0.00 | $-1.77 |
| EPS (Diluted) | $-17.68 | $-17.85 | $-9.28 | $-8.54 | $-6.40 | $-0.12 | $-2.05 | $-3.14 | $-0.00 | $-1.69 |
| Shares Outstanding (Diluted) | $1.1M | $1.2M | $1.3M | $1.5M | $3.3M | $5.2M | $5.3M | $5.3M | $5.4M | $5.7M |
Price
| Price | $2.16 |
| Market Cap | $18M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADAP · ANL · BLRX · EDSA · ERNA · GOVX · LNAI
Explore sector: Healthcare · Biotechnology
More sections of LPCN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks